H.C. Wainwright lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $11 from $12 and keeps a Buy rating on the shares following the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook
- Y-mAbs Therapeutics price target lowered to $20 from $21 at Oppenheimer
- Positive Outlook for Y-Mabs Therapeutics Amid Strategic Developments and NCCN Inclusion
- Y-mAbs Therapeutics Reports Q1 2025 Financial Results
- Cautious Outlook on Y-Mabs Therapeutics Amidst Competitive and Enrollment Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue